Revvity, IncNYSE: RVTY
Health Care · Health Care Equipment
$86.92
+0.35%
Vol: 953K
Research Digest
Friday, May 1, 2026
Revvity declares quarterly dividend of $0.07; Q1 earnings due May 5
Revvity announced a regular quarterly dividend of $0.07 per share payable Aug 7, 2026. The company will release Q1 2026 results before market open May 5 and present at BofA Securities Health Care Conference May 13. Faces headwinds from weak organic growth and declining margins. Barclays downgraded to Equal Weight from Overweight; Nephron upgraded to Hold.
Previous Market Intelligence
13 daysApr 30Revvity faces analyst caution on weak organic growth despite new product launchesNegative▶
Revvity faced 7.6% stock decline amid analyst caution on low-single-digit organic growth outlook. Company launched Signals BioDesign molecular cloning platform and scheduled Q1 earnings for May 5. Leadership and strategic partnership developments provide modest growth catalysts, but organic growth remains a concern.
Apr 16Revvity declared $0.07 quarterly dividend and announced Signals BioDesign cloud-based molecular cloning platformPositive▶
Revvity announced its regular quarterly dividend of $0.07 per share, payable May 8, 2026 to shareholders of record on April 17, 2026. The company unveiled Signals BioDesign, a cloud-based molecular cloning platform designed to simplify biotech and pharmaceutical R&D workflows. At SLAS2026, Revvity showcased multiple discovery platforms including Opera Phenix OptIQ high-content screening system and EnVision Nexus One multimode plate reader. The company is also collaborating with Eli Lilly to integrate Lilly TuneLab predictive models into Signals Xynthetica. Evercore ISI lowered its price target to $108 from $118.
Apr 15Revvity shareholders voting April 28 on annual items including shareholder proposals on executive stock retention.Neutral▶
Revvity annual shareholder meeting scheduled for April 28, 2026 via virtual webcast includes election of ten directors, ratifying Deloitte as auditor, and votes on shareholder proposals. Company beat Q1 estimates with $1.70 EPS versus $1.55 consensus. Stock up 4.9% over past week and 8.3% over past month. Analyst average price target of $118.13 suggests 31.6% upside.
Apr 14Revvity holds annual meeting on April 28 amid shareholder activism; positive Eli Lilly collaboration announced.Neutral▶
Revvity Inc. will hold its 2026 annual meeting virtually on April 28. Announced collaboration with Eli Lilly to make predictive models available through Signals Xynthetica. Shareholder activist proposed executive stock-retention requirements. Q4 revenue near $772 million with 6% reported growth. FY 2026 EPS guidance $5.350-$5.450. Consensus Moderate Buy with $118.13 target.
Apr 13Revvity holds annual shareholder meeting April 28; activist shareholder proposes stock retention policy.Neutral▶
Revvity scheduled virtual shareholder meeting for April 28 to vote on directors, auditor ratification, and executive compensation. Activist John Chevedden submitted proposal requiring top five executives to retain significant equity until retirement. Q1 earnings due April 27.
Apr 10Revvity launches Signals BioDesign cloud cloning platform; faces activist shareholder votes on April 28.Neutral▶
Revvity announced Signals BioDesign, a cloud-native molecular cloning solution to streamline biologics research workflows. Evercore ISI lowered price target to $108 from $118 on April 6. Annual meeting April 28 features activist-backed proposals for executive stock retention and special meeting rights. Q1 earnings expected April 27. Stock at $85.94.
Apr 9Revvity Inc acquires ACD/Labs to expand Signals software capabilities and reports Q3 earnings beat amid mixed fundamentals.Neutral▶
Revvity Inc (RVTY) announced definitive agreement to acquire ACD/Labs, global provider of scientific software supporting analytical characterization and molecular design in pharma and materials science. Acquisition expands Revvity Signals solutions for bridging analytical data to actionable insights. Q3 2025 EPS of $1.18 beat consensus estimate of $1.14 with 2.1% YoY revenue growth. Preliminary Q4 2025 revenue expected ~$772M with organic growth of ~4%, and FY2025 revenue expected ~$2,855M with organic growth ~3%. AI highlight includes Signals Xynthetica platform launch with Eli Lilly collaboration for predictive models in federated framework. Company scheduled to present at J.P. Morgan Healthcare Conference January 13, 2026. Regular quarterly dividend of $0.07 per share payable May 8, 2026. Stock up 0.29% weekly but down 9.64% monthly and 21.64% annually reflecting analyst concerns on mixed fundamentals and declining earnings. RVTY innovations in AI-enabled discovery position company for future growth despite near-term headwinds.
Apr 8Revvity collaborates with Eli Lilly on AI-driven drug discovery; shareholder activism challenges compensation.Neutral▶
Revvity announced collaboration with Eli Lilly to integrate Lilly TuneLab predictive models into Signals Xynthetica, accelerating AI-enabled drug discovery. Q4 2025 preliminary revenue ~$772M (organic +4%); FY2025 revenue ~$2.855B (organic +3%). 2026 guidance: mid-to-high single-digit organic growth, adjusted EPS $5.50-$5.70. Activist John Chevedden submitted proposal (March 2026) requiring top-five executives retain equity until retirement; board recommends voting against for April 28, 2026 annual meeting. Current price $85.94 (-9.64% month, -21.64% year). 18 analyst consensus "Moderate Buy" with $119.40 target, 39.2% upside.
Apr 7No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Apr 6Revvity collaboration with Eli Lilly on AI drug discovery; weak 2-3% organic growth guide.Neutral▶
Revvity announced collaboration with Eli Lilly integrating Lilly TuneLab predictive models into Signals Xynthetica AI platform. Q3 2025 EPS $1.18 beat $1.14. FY26 guidance 2-3% organic growth (weakest among peers), causing 20%+ share drop Feb 2026.
Apr 3Revvity shareholder meeting scheduled for April 28 with activist proposal on executive stock retention.Neutral▶
Annual meeting April 28, 2026 featuring vote on 10 directors and amendment allowing 25% shareholders to call special meetings. Activist shareholder John Chevedden submitted proposal requiring top five executives retain equity until retirement. Q4 2025 showed strong results with adjusted EPS 5.06 and 2026 revenue guidance of $2.96-2.99 billion.
Apr 2Revvity collaborates with Eli Lilly on AI drug discovery platform; unveils new products at SLAS2026; stock down 9.6% past month amid tariff concerns.Mixed▶
Revvity announced collaboration with Eli Lilly to integrate Lilly TuneLab predictive models into Signals Xynthetica platform for federated AI drug discovery. Company declared quarterly dividend of $0.07/share payable May 8, 2026. Unveiled new product launches at SLAS2026 including Opera Phenix OptIQ screening system and EnVision Nexus One multimode reader. Q3 2025 revenue grew 2.1% YoY. Stock down 9.6% in past month after tariff announcement concerns.
Apr 1Revvity collaborated with Eli Lilly on AI drug discovery; issued FY2026 guidance of $2.96-$2.99B.Mixed▶
Revvity reported Q4 2025 preliminary revenue of ~$772M with ~6% reported growth. FY2026 guidance of $2.96-$2.99B resulted in 20%+ share decline. Announced collaboration with Eli Lilly for federated AI-enabled drug discovery.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| RVTYREVVITY | $86.92 | +0.35% | -1.9% | 14.4x | 1.13 | $9.7B |
| ISRGINTUITIVE | $458.41 | +0.17% | +1.1% | 38.8x | 1.68 | $162.1B |
| ABTABBOTT | $89.66 | -1.25% | -11.3% | 15.0x | 0.78 | $157.8B |
| SYKSTRYKER | $296.89 | -5.79% | -5.2% | 18.8x | 0.93 | $120.7B |
| MDTMEDTRONIC | $80.38 | -0.73% | -6.2% | 13.4x | 0.76 | $104.0B |
| BSXBOSTON | $56.75 | -1.50% | -8.0% | 15.3x | 0.78 | $85.6B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price below 200d MA — bearish structure.